| References |
|
1. Dennis M.
Immunovant's new lead asset suffers first clinical setback in lupus. Accessed on 23/09/2026. Modified on 23/09/2026. firstwordpharma.com, https://firstwordpharma.com/story/8081036 |
|
2. Yap DYH, Hai J, Lee PCH, Zhou X, Lee M, Zhang Y, Wang M, Chen X. (2021)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci, 14 (5): 1769-1779. [PMID:33742786] |